A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

August 31, 2014

Study Completion Date

December 31, 2014

Conditions
Diabetic NephropathyType 2 Diabetes Mellitus
Interventions
DRUG

Placebo

Placebo capsules once daily

DRUG

CCX140-B

CCX140-B capsules once daily (Group B)

DRUG

CCX140-B

CCX140-B capsules once daily (Group C)

Trial Locations (83)

Unknown

Antwerp

Brussels

Edegem

Ghent

Leuven

Liège

Roeselare

Beroun

Brno

Hlučín

Neratovice

Nový Jičín

NZdar Nad Sazavou

Pardubice

Prague

Přelouč

Rakovník

Slaný

Třebíč

Uherský Brod

Uničov

Berlin

Bosenheim

Cologne

Deggingen

Dresden

Erlangen

Hanover

Heidelberg

Heilbronn

Hoyerswerda

Munich

Neuwied

Nuremberg

Pirna

Potsdam

Saarlouis

Speyer

Wiesbaden

Baja

Balatonfüred

Békéscsaba

Budapest

Debrecen

Eger

Gyula

Hatvan

Kaposvár

Kisvárda

Sátoraljaújhely

Szekszard, Tolna

Szikszó

Bialystok

Ciechanów

Gdansk

Grodzisk Mazowiecki

Krakow

Poznan

Radom

Rzeszów

Szczecin

Warsaw

Wroclaw

Bath

Belfast

Birmingham

Bristol

Chester

Coventry

Doncaster

Edmonton

Liverpool

Livingston

London

Londonderry

Manchester

Middlesbrough

Norfolk

Preston

Salford

Sheffield

Swansea

Welwyn Garden City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01447147 - A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy | Biotech Hunter | Biotech Hunter